Orchestra Biomed Holdings, Inc. · NASDAQ:OBIO
Orchestra Biomed — THT 2025
13 slides from Orchestra Biomed's conference presentation, 2025
Slide 1: Effects of AVIM Therapy in Subjects with Hypertension and Diastolic Dysfunction
Effects of AtrioVentricular Interval Modulation (AVIM) Therapy in Subjects with Hypertension and Diastolic Dysfunction Marat Fudim, MD, MHS Advanced Heart Failure Specialist, Cardiologist Duke University Health System
Slide 2: Disclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Nature of Financial Relationship Ineligible Company Grant/Research Supp
Slide 3: Atrioventricular Interval Modulation (AVIM) Therapy
Atrioventricular Interval Modulation (AVIM) Therapy AVIM Therapy Uses a Dual-chamber Pacemaker to Deliver Repeated Sequences of Short and Longer AV Intervals to Reduce Blood Pressure1 Short AV intervals: Reduce cardiac preload, immediately Designed to Immediately, Substantially and lowering blood pr
Slide 4: AVIM Therapy Shows Favorable Acute Hemodynamics
VXVHK? Acute Hemodynamics AVIM Therapy Shows Favorable AVIM Therapy Reduces Blood Pressure, Intra-Cardiac Volumes and Total Peripheral Resistance AV Sequential Pacing AVIM Therapy TPR↓ SBP↓ Baseline Baseline AV sequential pacing AVIM LV Pressure (mmHg) LV Pressure (mmHg) ESV↓ EDV↓ LV Volume (ml) N =
Slide 5: MODERATO II Prospective, Randomized, Double-Blind Pilot Study Reduces Systolic Blood Pressure
VXVHK? Double-Blind Pilot Study MODERATO II Prospective, Randomized, AVIM Therapy Significantly Reduces Systolic Blood Pressure 24-Hour aSBP oSBP 1 day 6 Months 6 Months 24 Months 0 Pacemaker Patients -3.1 -0.1 P =0.17 with Uncontrolled -1.5 P = 0.94 Δ in SBP (mmHg) P = 0.5 Hypertension Despite -5 0
Slide 6: Retrospective Analysis of MODERATO II Patients with Diastolic Dysfunction
Retrospective Analysis of MODERATO II Patients with Diastolic Dysfunction • Hypertension is the leading cause of diastolic dysfunction (DD). Both conditions are common in the elderly and contribute to the development of Heart Failure1 • Conducted a retrospective, treatment-blinded analysis of MODERA
Slide 7: Retrospective Analysis of MODERATO II Patients with Diastolic Dysfunction
Retrospective Analysis of MODERATO II Patients with Diastolic Dysfunction 47 Pacemaker Patients with Uncontrolled Hypertension Despite Medical Therapy LVEF ≥ 50% and Absence of HF Symptoms Suitable Echo N=36 22 Pts. 14 Pts. Diastolic Dysfunction No Diastolic Dysfunction DD+ DD- 12 Pts. 10 Pts. 11 Pt
Slide 8: Demographics
Demographics All DD+ DD- All DD+ DD- (n=36) (n=22) (n=14) (n=36) (n=22) (n=14) Age (yrs) 73.2± 8.8 74.0 ± 8.7 72.0 ± 9.2 oSBP 154.8±19.4 156.6±19.8 152.0±19.2 Gender 23 M / 13F 13M / 9 F 10M / 4F aSBP 136.2±9.3 136.3±10.0 136.0±8.5 Comorbidities LV EF (%) 62.8±5.7 62.9±6.2 62.6±5.2 AF (8) 22% (3) 14
Slide 9: Reduces SBP in Patients with Diastolic Dysfunction
AVIM Therapy Significantly Reduces SBP in Patients with Diastolic Dysfunction AVIM Therapy Significantly Reduces Office & Ambulatory Systolic BP Through 6 Months oSBP 24-Hour aSBP AVIM Therapy Control AVIM Therapy Control Δ -12.1 Δ -8.3 P<0.01 P=0.73 P=0.01 P=0.28 180 180 150 150 140 aSBP (mmHg) oSB
Slide 10: AVIM Therapy Improved Diastolic Dysfunction: e' Increase
VXVHK? AVIM Therapy Improved Diastolic Dysfunction AVIM Therapy Significantly Increased e’ from 5.9 to 8.8 cm/sec % of Patients with Normal e’ Increased from 16% to 58% AVIM Therapy Increased e’ Indicating Improved Normal Myocardial Relaxation e’ ≥ 8 cm/sec AVIM Therapy Control P<0.01 P=0.34 DD+ AVI
Slide 11: AVIM Therapy Improved Diastolic Dysfunction: E/A Ratio
VXVHK? AVIM Therapy Improved Diastolic Dysfunction AVIM Therapy Significantly Increased the E/A Ratio from 0.8 to 1.6, % of Patients with Normal E/A Increased from 42% to 73% AVIM Therapy Increased E/A Ratio Suggesting Improved Normal Myocardial Relaxation and Improved Diastolic Compliance E/A ≥ 0.8
Slide 12: AVIM Therapy Effects in Diastolic Dysfunction Patients
AVIM Therapy Effects in Diastolic Dysfunction Patients AVIM Therapy Significantly Increased e’, E, and E/A with No Significant Changes in EF and LA Size Echocardiographic Markers of Diastolic Dysfunction AVIM Therapy (N=12) Control (N=10) Baseline 6M 6M - BL Baseline 6M 6M-BL LV EF (%) 64.8 ± 6.8 61
Slide 13: Conclusions
Conclusions • In MODERATO II, a study of hypertensive pacemaker patients with LVEF ≥ 50% and NYHA < II, 61% of subjects had echocardiographic evidence of Diastolic Dysfunction • AVIM therapy significantly reduced SBP in patients with Diastolic Dysfunction • AVIM therapy improved myocardial relaxatio